News & Events
Press Releases
Agomab Announces Launch of Initial Public Offering
ANTWERP, Belgium, February 2, 2026. Agomab Therapeutics NV (“Agomab”), a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need, today announced the launch of its initial public offering of 12,500,000 American Depositary Shares (“ADSs”), each ADS representing
Agomab Announces Positive Phase 1 Interim Results with AGMB-447 in Healthy Participants and Initiation of Idiopathic Pulmonary Fibrosis Cohort
Antwerp, Belgium, January 8, 2026 Agomab Therapeutics NV (‘Agomab’), a clinical-stage biopharmaceutical company focused on fibrosis, today announced positive interim results of the Phase 1 study of AGMB-447 in healthy participants. AGMB-447 is an inhaled lung-restricted small molecule inhibitor of ALK5 (or TGFβR1) intended for the treatment of Idiopathic Pulmonary Fibrosis (IPF).
Loading...
End of content
No more pages to load
Agomab Announces Positive Topline Phase 2a Data for Ontunisertib in Fibrostenosing Crohn’s Disease
Antwerp, Belgium, November 17, 2025. Agomab Therapeutics NV (‘Agomab’) today announced positive data from 103 participants completing 12 weeks of treatment in the STENOVA Phase 2a clinical trial for ontunisertib (AGMB-129), an investigational oral gastro-intestinal (GI)-restricted small molecule inhibitor of ALK5 (TGFβ RI or ALK5) for the potential treatment of Fibrostenosing Crohn’s Disease (FSCD).
Late-Breaking Interim STENOVA Data for AGMB-129 in Fibrostenosing Crohn’s to be Presented at Digestive Disease Week® 2025
Antwerp, Belgium, April 10, 2025 – Agomab Therapeutics NV (‘Agomab’) today announced that interim data from the ongoing STENOVA1 Phase 2a clinical trial for AGMB-129, an oral gastro-intestinal (GI)-restricted small molecule inhibitor of ALK5 (TGFβ-RI or ALK5) for the potential treatment of Fibrostenosing Crohn’s Disease (FSCD), will be presented as a late-breaking presentation at Digestive
Agomab Announces Positive Topline Phase 2a Interim Results for AGMB-129 in Fibrostenosing Crohn’s Disease
— AGMB-129 hit all primary and secondary endpoints in interim read-out from 44 patients after 12 weeks treatment — Detailed interim STENOVA results to be presented at future scientific conference — STENOVA clinical trial on track to report full results in the fourth quarter of 2025 — Open-label extension study initiated
Loading...
End of content
No more pages to load
Agomab Announces the Appointment of Former Sandoz CFO Colin Bond to its Board of Directors
Antwerp, Belgium, November 18, 2024 – Agomab Therapeutics NV (‘Agomab’) today announced the appointment of Colin Bond to the company’s Board of Directors as a non-executive Director and Chairman of the Audit Committee. With an extensive career in finance that spans over three decades at leading international corporations, Colin also brings fifteen years of experience
Agomab Announces $89 Million Series D Financing to Support Broad Fibrosis- focused Pipeline
Antwerp, Belgium, October 25, 2024 – Agomab Therapeutics NV (‘Agomab’) today announced a $89 million (€82.1 million) Series D financing round, with participation from new investors Sanofi and Invus, as well as existing investors. The proceeds from the Series D will be used to further advance the ongoing clinical development of Agomab’s lead candidate, AGMB-129,
Agomab Bolsters Executive Team with Appointment of Pierre Kemula as Chief Financial Officer
Antwerp, Belgium, July 11, 2024 Agomab Therapeutics NV (‘Agomab’) today announced that Pierre Kemula will join the company as Chief Financial Officer (CFO) effective November 1, 2024, bringing more than 15 years of experience in global biotech financial leadership. Mr. Kemula joins Agomab from CureVac N.V. (Nasdaq: CVAC), where he currently serves as CFO. In
Agomab Appoints Industry Veteran David Epstein as Chairman of its Board of Directors
Antwerp, Belgium, July 9, 2024 Agomab Therapeutics NV (‘Agomab’) today announced that it has appointed David Epstein as non-executive board member and Chairman of its Board of Directors. David is an industry veteran and most recently served as Seagen’s Chief Executive Officer and as a member of its Board of Directors. Under his leadership, Seagen
Agomab Receives FDA Orphan Drug Designation for AGMB-447 in Idiopathic Pulmonary Fibrosis
Antwerp, Belgium, June 6, 2024 Agomab Therapeutics NV (‘Agomab’) today announced that it has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for AGMB-447, its inhaled, small molecule inhibitor of ALK5. Agomab is evaluating AGMB-447 as a potential treatment for Idiopathic Pulmonary Fibrosis (IPF) in a Phase 1 clinical trial (NCT06181370).
Loading...
End of content
No more pages to load
Agomab Starts Phase 1 Clinical Study for AGMB-447 in Healthy Subjects and Patients with Idiopathic Pulmonary Fibrosis
Ghent, Belgium, December 14, 2023 Agomab Therapeutics NV (‘Agomab’) today announced that it has dosed the first subject in a first-in-human Phase 1 clinical study of AGMB-447, an inhaled lung-restricted small molecule inhibitor of ALK5 (TGFβRI or ALK5). The study is evaluating AGMB-447 in healthy subjects and in patients with idiopathic pulmonary fibrosis (IPF).
Agomab Appoints Angelika Jahreis as Member of the Board of Directors and Andrea Sáez as Chief Development Officer
Ghent, Belgium, November 29, 2023 – Agomab Therapeutics NV (‘Agomab’), a company developing differentiated programs with disease-modifying potential in fibrotic diseases, announced today the appointment of Angelika Jahreis, MD, PhD, as an independent non-executive director to Agomab’s Board of Directors, while Andrea Sáez, PhD, will join Agomab’s executive leadership team as Chief Development Officer. As
Agomab Raises $100 Million Series C to Advance Fibrosis-focused Pipeline
– Agomab Therapeutics NV (‘Agomab’) today announced the closing of a $100 million (€94.9 million) Series C financing round led by Fidelity Management & Research Company, with participation from new investors EQT Life Sciences (EQT), Canaan, Dawn Biopharma, a platform controlled by KKR, and existing investors.
Agomab Receives FDA Fast Track Designation for AGMB-129 in Fibrostenosing Crohn’s Disease and Starts STENOVA Phase 2a Clinical Trial
– Agomab Therapeutics NV (‘Agomab’) today announced that it received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for AGMB-129 for the potential treatment of Fibrostenosing Crohn’s Disease (FSCD). In addition, Agomab has initiated its STENOVA Phase 2a clinical trial evaluating AGMB-129.
Agomab Reports Positive Phase 1 Results with AGMB-129, a GI-restricted ALK5 Inhibitor for Fibrostenosing Crohn’s Disease
– Agomab Therapeutics NV (‘Agomab’) today announced positive clinical results from its Phase 1 study evaluating AGMB-129, an oral gastro-intestinal (GI)-restricted small molecule kinase inhibitor of ALK5 (TGFβRI or ALK5), intended for the treatment of Fibrostenosing Crohn’s Disease (FSCD).
Loading...
End of content
No more pages to load
Agomab Therapeutics Selected as One of Fierce Biotech’s “Fierce 15” Companies of 2022
Agomab Therapeutics NV (‘Agomab’) today announced that Fierce Biotech has named the company as one of 2022’s Fierce 15 biotechnology companies, designating it as one of the most promising early-stage biotechnology companies in the industry.
Agomab Raises Additional $40.5 Million Through Series B Extension Bringing Total Amount to $114 Million
Agomab Therapeutics NV (‘Agomab’) today announced it has extended its Series B financing round with an additional close of $40.5 million (€38.4 million), bringing the total Series B amount raised to $114 million.
Agomab to Present at 40th Annual J.P. Morgan Healthcare Conference and Announces Additional Upcoming Conference Participations in Q1
Agomab Therapeutics NV (‘Agomab’) today announced that Tim Knotnerus, Chief Executive Officer, will present a company overview and update at the virtual 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13 at 8:00 a.m. ET (14:00 CET).
Loading...
End of content
No more pages to load
Agomab Expands Team with Reginald Brys as Head of Research and Maria Nichol as Head of IP
Agomab Therapeutics NV (‘Agomab’) today announced the expansion of its team with two key hires: Reginald Brys will join as Head of Research and Maria Nichol will become Head of Intellectual Property. Each brings more than 20 years of highly valuable experience in identifying and driving novel drug candidate development and international patent law and strategy, respectively.
Agomab Therapeutics Completes Acquisition of Origo Biopharma
Agomab Therapeutics NV (‘Agomab’) announced today the closing of the Origo Biopharma acquisition. The transaction, first announced on October 28th, 2021, combines Spanish biotech Origo Biopharma and its pipeline of organ-restricted small molecule drug candidates targeting the transforming growth factor beta (TGF-β) pathway with Agomab’s hepatocyte growth factor (HGF)-targeting programs.
Agomab Therapeutics to Acquire Origo Biopharma
Agomab Therapeutics NV (‘Agomab’) announced today that it has entered into a definitive agreement under which it will acquire Origo Biopharma S.L., a Spanish clinical-stage biotechnology company developing organ-restricted small molecule drug candidates targeting the transforming growth factor beta (TGF-β) pathway for the treatment of fibrosis-related disorders.
Loading...
End of content
No more pages to load
Loading...
End of content
No more pages to load
Agomab Announces Launch of Initial Public Offering
ANTWERP, Belgium, February 2, 2026. Agomab Therapeutics NV (“Agomab”), a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need, today announced the launch of its initial public offering of 12,500,000 American Depositary Shares (“ADSs”), each ADS representing
Agomab Announces Positive Phase 1 Interim Results with AGMB-447 in Healthy Participants and Initiation of Idiopathic Pulmonary Fibrosis Cohort
Antwerp, Belgium, January 8, 2026 Agomab Therapeutics NV (‘Agomab’), a clinical-stage biopharmaceutical company focused on fibrosis, today announced positive interim results of the Phase 1 study of AGMB-447 in healthy participants. AGMB-447 is an inhaled lung-restricted small molecule inhibitor of ALK5 (or TGFβR1) intended for the treatment of Idiopathic Pulmonary Fibrosis (IPF).
Agomab Announces Positive Topline Phase 2a Data for Ontunisertib in Fibrostenosing Crohn’s Disease
Antwerp, Belgium, November 17, 2025. Agomab Therapeutics NV (‘Agomab’) today announced positive data from 103 participants completing 12 weeks of treatment in the STENOVA Phase 2a clinical trial for ontunisertib (AGMB-129), an investigational oral gastro-intestinal (GI)-restricted small molecule inhibitor of ALK5 (TGFβ RI or ALK5) for the potential treatment of Fibrostenosing Crohn’s Disease (FSCD).
Late-Breaking Interim STENOVA Data for AGMB-129 in Fibrostenosing Crohn’s to be Presented at Digestive Disease Week® 2025
Antwerp, Belgium, April 10, 2025 – Agomab Therapeutics NV (‘Agomab’) today announced that interim data from the ongoing STENOVA1 Phase 2a clinical trial for AGMB-129, an oral gastro-intestinal (GI)-restricted small molecule inhibitor of ALK5 (TGFβ-RI or ALK5) for the potential treatment of Fibrostenosing Crohn’s Disease (FSCD), will be presented as a late-breaking presentation at Digestive
Agomab Announces Positive Topline Phase 2a Interim Results for AGMB-129 in Fibrostenosing Crohn’s Disease
— AGMB-129 hit all primary and secondary endpoints in interim read-out from 44 patients after 12 weeks treatment — Detailed interim STENOVA results to be presented at future scientific conference — STENOVA clinical trial on track to report full results in the fourth quarter of 2025 — Open-label extension study initiated
Agomab Announces the Appointment of Former Sandoz CFO Colin Bond to its Board of Directors
Antwerp, Belgium, November 18, 2024 – Agomab Therapeutics NV (‘Agomab’) today announced the appointment of Colin Bond to the company’s Board of Directors as a non-executive Director and Chairman of the Audit Committee. With an extensive career in finance that spans over three decades at leading international corporations, Colin also brings fifteen years of experience
Agomab Announces $89 Million Series D Financing to Support Broad Fibrosis- focused Pipeline
Antwerp, Belgium, October 25, 2024 – Agomab Therapeutics NV (‘Agomab’) today announced a $89 million (€82.1 million) Series D financing round, with participation from new investors Sanofi and Invus, as well as existing investors. The proceeds from the Series D will be used to further advance the ongoing clinical development of Agomab’s lead candidate, AGMB-129,
Agomab Bolsters Executive Team with Appointment of Pierre Kemula as Chief Financial Officer
Antwerp, Belgium, July 11, 2024 Agomab Therapeutics NV (‘Agomab’) today announced that Pierre Kemula will join the company as Chief Financial Officer (CFO) effective November 1, 2024, bringing more than 15 years of experience in global biotech financial leadership. Mr. Kemula joins Agomab from CureVac N.V. (Nasdaq: CVAC), where he currently serves as CFO. In
Agomab Appoints Industry Veteran David Epstein as Chairman of its Board of Directors
Antwerp, Belgium, July 9, 2024 Agomab Therapeutics NV (‘Agomab’) today announced that it has appointed David Epstein as non-executive board member and Chairman of its Board of Directors. David is an industry veteran and most recently served as Seagen’s Chief Executive Officer and as a member of its Board of Directors. Under his leadership, Seagen
Agomab Receives FDA Orphan Drug Designation for AGMB-447 in Idiopathic Pulmonary Fibrosis
Antwerp, Belgium, June 6, 2024 Agomab Therapeutics NV (‘Agomab’) today announced that it has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for AGMB-447, its inhaled, small molecule inhibitor of ALK5. Agomab is evaluating AGMB-447 as a potential treatment for Idiopathic Pulmonary Fibrosis (IPF) in a Phase 1 clinical trial (NCT06181370).
Agomab Starts Phase 1 Clinical Study for AGMB-447 in Healthy Subjects and Patients with Idiopathic Pulmonary Fibrosis
Ghent, Belgium, December 14, 2023 Agomab Therapeutics NV (‘Agomab’) today announced that it has dosed the first subject in a first-in-human Phase 1 clinical study of AGMB-447, an inhaled lung-restricted small molecule inhibitor of ALK5 (TGFβRI or ALK5). The study is evaluating AGMB-447 in healthy subjects and in patients with idiopathic pulmonary fibrosis (IPF).
Agomab Appoints Angelika Jahreis as Member of the Board of Directors and Andrea Sáez as Chief Development Officer
Ghent, Belgium, November 29, 2023 – Agomab Therapeutics NV (‘Agomab’), a company developing differentiated programs with disease-modifying potential in fibrotic diseases, announced today the appointment of Angelika Jahreis, MD, PhD, as an independent non-executive director to Agomab’s Board of Directors, while Andrea Sáez, PhD, will join Agomab’s executive leadership team as Chief Development Officer. As
Agomab Raises $100 Million Series C to Advance Fibrosis-focused Pipeline
– Agomab Therapeutics NV (‘Agomab’) today announced the closing of a $100 million (€94.9 million) Series C financing round led by Fidelity Management & Research Company, with participation from new investors EQT Life Sciences (EQT), Canaan, Dawn Biopharma, a platform controlled by KKR, and existing investors.
Agomab Receives FDA Fast Track Designation for AGMB-129 in Fibrostenosing Crohn’s Disease and Starts STENOVA Phase 2a Clinical Trial
– Agomab Therapeutics NV (‘Agomab’) today announced that it received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for AGMB-129 for the potential treatment of Fibrostenosing Crohn’s Disease (FSCD). In addition, Agomab has initiated its STENOVA Phase 2a clinical trial evaluating AGMB-129.
Agomab Reports Positive Phase 1 Results with AGMB-129, a GI-restricted ALK5 Inhibitor for Fibrostenosing Crohn’s Disease
– Agomab Therapeutics NV (‘Agomab’) today announced positive clinical results from its Phase 1 study evaluating AGMB-129, an oral gastro-intestinal (GI)-restricted small molecule kinase inhibitor of ALK5 (TGFβRI or ALK5), intended for the treatment of Fibrostenosing Crohn’s Disease (FSCD).
Agomab Therapeutics Selected as One of Fierce Biotech’s “Fierce 15” Companies of 2022
Agomab Therapeutics NV (‘Agomab’) today announced that Fierce Biotech has named the company as one of 2022’s Fierce 15 biotechnology companies, designating it as one of the most promising early-stage biotechnology companies in the industry.
Agomab Raises Additional $40.5 Million Through Series B Extension Bringing Total Amount to $114 Million
Agomab Therapeutics NV (‘Agomab’) today announced it has extended its Series B financing round with an additional close of $40.5 million (€38.4 million), bringing the total Series B amount raised to $114 million.
Agomab to Present at 40th Annual J.P. Morgan Healthcare Conference and Announces Additional Upcoming Conference Participations in Q1
Agomab Therapeutics NV (‘Agomab’) today announced that Tim Knotnerus, Chief Executive Officer, will present a company overview and update at the virtual 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13 at 8:00 a.m. ET (14:00 CET).
Agomab Expands Team with Reginald Brys as Head of Research and Maria Nichol as Head of IP
Agomab Therapeutics NV (‘Agomab’) today announced the expansion of its team with two key hires: Reginald Brys will join as Head of Research and Maria Nichol will become Head of Intellectual Property. Each brings more than 20 years of highly valuable experience in identifying and driving novel drug candidate development and international patent law and strategy, respectively.
Agomab Therapeutics Completes Acquisition of Origo Biopharma
Agomab Therapeutics NV (‘Agomab’) announced today the closing of the Origo Biopharma acquisition. The transaction, first announced on October 28th, 2021, combines Spanish biotech Origo Biopharma and its pipeline of organ-restricted small molecule drug candidates targeting the transforming growth factor beta (TGF-β) pathway with Agomab’s hepatocyte growth factor (HGF)-targeting programs.
Agomab Therapeutics to Acquire Origo Biopharma
Agomab Therapeutics NV (‘Agomab’) announced today that it has entered into a definitive agreement under which it will acquire Origo Biopharma S.L., a Spanish clinical-stage biotechnology company developing organ-restricted small molecule drug candidates targeting the transforming growth factor beta (TGF-β) pathway for the treatment of fibrosis-related disorders.
Loading...
End of content
No more pages to load
